Baugh & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.02M | Sell |
208,631
-16,386
| -7% | -$429K | 2.22% | 19 |
|
|
2026
Q1 | $6.32M | Buy |
225,017
+12,727
| +6% | +$339K | 2.73% | 16 |
|
|
2025
Q4 | $4.88M | Buy |
212,290
+34,733
| +20% | +$876K | 2.4% | 19 |
|
|
2025
Q3 | $4.2M | Sell |
177,557
-6,802
| -4% | -$168K | 2.09% | 25 |
|
|
2025
Q2 | $4.17M | Sell |
184,359
-10,292
| -5% | -$240K | 2.17% | 23 |
|
|
2025
Q1 | $4.71M | Buy |
194,651
+483
| +0.2% | +$12.6K | 2.38% | 24 |
|
|
2024
Q4 | $4.97M | Buy |
194,168
+29,025
| +18% | +$787K | 2.58% | 15 |
|
|
2024
Q3 | $4.6M | Buy |
165,143
+997
| +0.6% | +$29.1K | 2.37% | 22 |
|
|
2024
Q2 | $4.79M | Sell |
164,146
-7,360
| -4% | -$203K | 2.49% | 21 |
|
|
2024
Q1 | $4.76M | Buy |
171,506
+43,907
| +34% | +$1.22M | 2.53% | 18 |
|
|
2023
Q4 | $3.67M | Sell |
127,599
-5,813
| -4% | -$176K | 2.11% | 25 |
|
|
2023
Q3 | $4.43M | Buy |
133,412
+19,323
| +17% | +$683K | 2.77% | 16 |
|
|
2023
Q2 | $4.18M | Buy |
114,089
+1,890
| +2% | +$73.6K | 2.52% | 17 |
|
|
2023
Q1 | $4.66M | Sell |
112,199
-2,270
| -2% | -$98K | 2.98% | 14 |
|
|
2022
Q4 | $5.87M | Sell |
114,469
-120
| -0.1% | -$5.75K | 3.8% | 9 |
|
|
2022
Q3 | $5.01M | Buy |
114,589
+1,538
| +1% | +$74.7K | 3.55% | 10 |
|
|
2022
Q2 | $5.93M | Sell |
113,051
-1,189
| -1% | -$60.6K | 3.99% | 8 |
|
|
2022
Q1 | $5.91M | Sell |
114,240
-355
| -0.3% | -$18.4K | 3.48% | 11 |
|
|
2021
Q4 | $6.77M | Sell |
114,595
-85
| -0.1% | -$4.21K | 3.74% | 8 |
|
|
2021
Q3 | $4.93M | Sell |
114,680
-187
| -0.2% | -$8.28K | 3.02% | 12 |
|
|
2021
Q2 | $4.5M | Sell |
114,867
-1,000
| -0.9% | -$38.9K | 2.79% | 12 |
|
|
2021
Q1 | $4.2M | Buy |
115,867
+12,419
| +12% | +$441K | 2.77% | 13 |
|
|
2020
Q4 | $3.81M | Sell |
103,448
-1,817
| -2% | -$66.6K | 2.71% | 17 |
|
|
2020
Q3 | $3.67M | Sell |
105,265
-1,571
| -1% | -$55.1K | 2.88% | 14 |
|
|
2020
Q2 | $3.31M | Buy |
106,836
+3,147
| +3% | +$107K | 2.65% | 17 |
|
|
2020
Q1 | $3.21M | Sell |
103,689
-1,754
| -2% | -$59.8K | 3.1% | 14 |
|
|
2019
Q4 | $3.92M | Buy |
105,443
+3,474
| +3% | +$124K | 2.86% | 14 |
|
|
2019
Q3 | $3.48M | Buy |
101,969
+4,488
| +5% | +$163K | 2.69% | 20 |
|
|
2019
Q2 | $4.01M | Sell |
97,481
-2,272
| -2% | -$90.2K | 3.18% | 7 |
|
|
2019
Q1 | $4.02M | Sell |
99,753
-731
| -0.7% | -$29.3K | 3.22% | 9 |
|
|
2018
Q4 | $4.16M | Sell |
100,484
-428
| -0.4% | -$17.8K | 3.58% | 4 |
|
|
2018
Q3 | $4.22M | Buy |
100,912
+854
| +0.9% | +$32.9K | 3.37% | 7 |
|
|
2018
Q2 | $3.44M | Sell |
100,058
-8,302
| -8% | -$284K | 3% | 11 |
|
|
2018
Q1 | $3.65M | Buy |
108,360
+9,098
| +9% | +$313K | 2.94% | 13 |
|
|
2017
Q4 | $3.41M | Buy |
+99,262
| New | +$3.38M | 2.88% | 18 |
|
Other funds holding PFE
Baugh & Associates's PFE Position: Q2 2026 in Review
Baugh & Associates reduced its Pfizer (PFE) stake by 7.3% in Q2 2026, selling an estimated $429K and leaving 208,631 shares worth $5.02M. The position accounts for 2.22% of the portfolio, ranked #19.
Baugh & Associates first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $6.77M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Baugh & Associates held 208,631 shares of Pfizer worth $5.02M as of Q2 2026.
- Baugh & Associates sold 16,386 Pfizer shares in Q2 2026, an estimated $429K.
- Pfizer made up 2.22% of Baugh & Associates's portfolio in Q2 2026, its #19 holding.
- Baugh & Associates first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Baugh & Associates's Pfizer position peaked at $6.77M in Q4 2021.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Baugh & Associates's 13F filing for Q2 2026, filed 13 Jul 2026.